Immunoproteomic identification of MbovP579, a promising diagnostic biomarker for serological detection of Mycoplasma bovis infection

Farhan Anwar Khan,Muhammad Faisal,Jin Chao,Kai Liu,Xi Chen,Gang Zhao,Harish Menghwar,Hui Zhang,Xifang Zhu,Muhammad Asif Rasheed,Chenfei He,Changmin Hu,Yingyu Chen,Eric Baranowski,Huanchun Chen,Aizhen Guo
DOI: https://doi.org/10.18632/oncotarget.9799
2016-06-02
Oncotarget
Abstract:A lack of knowledge regarding the antigenic properties of Mycoplasma bovis proteins prevents the effective control of bovine infections using immunological approaches. In this study, we detected and characterized a specific and sensitive M. bovis diagnostic biomarker. After M. bovis total proteins and membrane fractions were separated with two dimensional gel electrophoresis, proteins reacting with antiserawere detected using MALDI-TOF MS. Thirty-nine proteins were identified, 32 of which were previously unreported. Among them, immunoinformatics predicted eight antigens, encoded by Mbov_0106, 0116, 0126, 0212, 0275, 0579, 0739, and 0789, to have high immunological value. These genes were expressed in E. coli after mutagenesis of UGA to UGG using overlap extension PCR. A lipoprotein, MbovP579, encoded by a functionally unknown gene, was a sensitive and specific antigen for detection of antibodies in sera from both M. bovis-infected and vaccinated cattle. The specificity of MbovP579 was confirmed by its lack of cross-reactivity with other mycoplasmas, including Mycoplasma agalactiae. An iELISA based on rMbovP579 detected seroconversion 7 days post-infection (dpi). The ELISA had sensitivity of 90.2% (95% CI: 83.7%, 94.3%) and a specificity of 97.8% (95% CI: 88.7%, 99.6%) with clinical samples. Additional comparative studies showed that both diagnostic and analytic sensitivities of the ELISA were higher than those of a commercially available kit (p<0.01). We have thus detected and characterized the novel antigen, MbovP579, and established an rMbovP579-based ELISA as a highly sensitive and specific method for the early diagnosis of M. bovis infection.
What problem does this paper attempt to address?
### Problems the paper attempts to solve This paper aims to solve the problem of the lack of sensitive and specific antigens in the diagnosis of Mycoplasma bovis (M. bovis) infection. Specifically, the study attempts to identify and characterize a new diagnostic biomarker through immunoproteomics and immunoinformatics methods to achieve early and accurate detection of M. bovis infection. #### Background problems 1. **Limitations of existing diagnostic methods**: - Currently, the main methods for controlling M. bovis are management practices and antibiotic treatment. However, M. bovis is naturally resistant to antibiotics, resulting in the ineffectiveness of many commercial antibiotics. - Although existing serological diagnostic methods can detect M. bovis - specific IgG, there is still room for improvement in terms of sensitivity and specificity. 2. **Challenges in antigen recognition**: - Insufficient understanding of the antigenic properties of M. bovis proteins limits the ability to effectively control bovine infections using immunological methods. - There is a need to find highly conserved, sensitive, and specific membrane proteins or membrane - associated proteins as new serological diagnostic targets. #### Research objectives - **Identify new antigens**: Screen out potential M. bovis antigens through immunoproteomics and immunoinformatics methods. - **Verify antigen performance**: Evaluate the immunoreactivity and specificity of these antigens after recombinant protein expression. - **Develop diagnostic tools**: Establish an indirect ELISA (iELISA) based on the best candidate antigen MbovP579 and evaluate its diagnostic performance in actual samples. ### Conclusions Through the above methods, the research team successfully identified and verified a new antigen MbovP579, which has high sensitivity and specificity and can effectively detect serum antibodies in M. bovis - infected animals. The iELISA based on rMbovP579 shows better diagnostic performance than commercial kits, providing a new tool for the early diagnosis of M. bovis infection. ### Formulas and data - **Sensitivity and specificity**: \[ \text{Sensitivity}=\frac{\text{True positive}}{\text{True positive}+\text{False negative}} = 90.2\% \quad (95\% \text{confidence interval}: 83.7\%, 94.3\%) \] \[ \text{Specificity}=\frac{\text{True negative}}{\text{True negative}+\text{False positive}} = 97.8\% \quad (95\% \text{confidence interval}: 88.7\%, 99.6\%) \] - **Kappa consistency value**: \[ Kappa = 0.7108 \] These results indicate that the iELISA based on rMbovP579 has high reliability and accuracy in the early diagnosis of M. bovis infection.